Current Cancer Drug Targets

Editor-in-Chief

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 4 Issue: 7, November

Extracellular Tropomyosin: A Novel Common Pathway Target for Anti- Angiogenic Therapy

Volume:4   Issue: 7
Pp: 543-553
Fernando Donate, Keith McCrae, David E. Shaw and Andrew P. Mazar
DOI: 10.2174/1568009043332781
Published on: 01 March, 2012

Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy

Volume:4   Issue: 7
Pp: 555-567
Hitoshi Yoshiji, Shigeki Kuriyama, Ryuichi Noguchi and Hiroshi Fukui
DOI: 10.2174/1568009043332790
Published on: 01 March, 2012

Targeting Apoptosis Pathways in Cancer Therapy

Volume:4   Issue: 7
Pp: 569-576
Simone Fulda and Klaus-Michael Debatin
DOI: 10.2174/1568009043332763
Published on: 01 March, 2012

Chemotherapeutic Agents That Induce Mitochondrial Apoptosis

Volume:4   Issue: 7
Pp: 577-590
Tadashi Asakura and Kiyoshi Ohkawa
DOI: 10.2174/1568009043332772
Published on: 01 March, 2012

Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers

Volume:4   Issue: 7
Pp: 591-596
Shiaw-Der Yang
DOI: 10.2174/1568009043332817
Published on: 01 March, 2012

Alphaviruses and their Derived Vectors as Anti-Tumor Agents

Volume:4   Issue: 7
Pp: 597-607
Gregory J. Atkins, James W. P. Smyth, Marina N. Fleeton, Sareen E. Galbraith and Brian J. Sheahan
DOI: 10.2174/1568009043332754
Published on: 01 March, 2012

The Life Cycle of Cutaneous T Cell Lymphoma Reveals Opportunities for Targeted Drug Therapy

Volume:4   Issue: 7
Pp: 609-619
Carole L Berger and Richard Edelson
DOI: 10.2174/1568009043332808
Published on: 01 March, 2012